Get inspired by this Museum of Failure!
The newly opened 'Museum of Failure' in Sweden on failed innovations is a lesson in embracing your errors
Curated By: Madhu Kapparath
Exubera
2006-2007
The pharmaceutical company Pfizer developed an inhalable insulin. The biggest advantage was that the insulin no longer needed to be injected with syringes. Following the product approval in the US and Europe, more than $2 billion was invested in a clinical development program. Patients liked this innovative solution, and it was expected to be very successful. Unfortunately, the inhaler was far too big and uncomfortable to carry. It was also complicated to use and required extensive instructions. Exubera was an expensive failure.
2006-2007
The pharmaceutical company Pfizer developed an inhalable insulin. The biggest advantage was that the insulin no longer needed to be injected with syringes. Following the product approval in the US and Europe, more than $2 billion was invested in a clinical development program. Patients liked this innovative solution, and it was expected to be very successful. Unfortunately, the inhaler was far too big and uncomfortable to carry. It was also complicated to use and required extensive instructions. Exubera was an expensive failure.
